MEDI 3414Alternative Names: Live attenuated nasal spray vaccine for H1N1 - MedImmune; MEDI-3414; Monovalent live attenuated pandemic influenza vaccine - MedImmune; Pandemic flu vaccine - MedImmune; Pandemic H1N1 influenza vaccine - MedImmune; Pandemic vaccines - MedImmune/NIAID
Latest Information Update: 16 Feb 2010
At a glance
- Originator MedImmune; National Institute of Allergy and Infectious Diseases
- Developer MedImmune
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype